Role of P-glycoprotein in pharmacokinetics and its clinical implications

Yaoxue Xuebao

Volumn 40, Issue 8, 2005, Pages 673-679

  Su, Cheng Ye ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Drug drug interactions; P glycoprotein; Pharmacokinetics

Indexed keywords

GLYCOPROTEIN P;

ANIMAL; BLOOD BRAIN BARRIER; CHEMISTRY; DRUG INTERACTION; GENETIC POLYMORPHISM; GENETICS; HUMAN; INTESTINE ABSORPTION; METABOLISM; PHARMACOGENETICS; PHYSIOLOGY; PLACENTA; REVIEW;

ANIMALS; BLOOD-BRAIN BARRIER; DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; P-GLYCOPROTEIN; PHARMACOGENETICS; PLACENTA; POLYMORPHISM, GENETIC;

EID: 26844581305     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants [J]. Biochim Biophys Acta, 1976,455(1):152-162.
2. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter [J]. Annu Rev Biochem, 1993,62:385-427.
3. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance [J]. Clin Pharmacol Ther, 2004,75 (1):13-33.
4. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein [J]. Clin Pharmacokinet, 2001,40(3): 159-168.
5. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications [J]. Clin Pharmacokinet, 2003,42(1):59-98.
6. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J]. Annu Rev Pharmacol Toxicol, 1999,39: 361-398.
7. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter [J]. Annu Rev Pharmacol Toxicol, 2003,43:285-307.
8. Mizuno N, Niwa T, Yotsumoto Y, et al. Impact of drug transporter studies on drug discovery and development [J]. Pharmacol Rev, 2003,55(3):425-461.
9. Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes [J]. Annu Rev Pharmacol Toxicol, 2001,41:535-567.
10. Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications [J]. Clin Pharmacokinet, 2004,43(9):553-576.
11. Yamazaki M, Neway WE, Ohe T, et al. In vitro substrate identification studies for p-glycoprotein mediated transport: species difference and predictability of in vitro results [J]. J Pharmacol Exp Ther, 2001,296(3): 723-735.
12. Hall SD. Molecular and physical mechanisms of first-pass extraction [J]. Drug Metab Dispos, 1999,27(2):161-166.
13. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion [J]. Xenobiotica, 2001,31(8-9):469-497.
14. Bao JF. P-glycoprotein on the blood-brain barrier [J]. Foreign Med Sci (Pharmacy) , 2000,27(3):154-158.
15. Taylor EM. The impact of efflux transporters in the brain on the development of drugs for CNS disorders [J]. Clin Pharmacokinet, 2002,41(2):81-92.
16. de Boer AG, van der Sandt IC, Gaillard PJ. The role of drug transporters at the blood-brain barrier [J]. Annu Rev Pharmacol Toxicol, 2003,43:629-656.
17. Su CY. Clinical Pharmacokinetics [M]. Beijing: Science Press, 2003.17-27.
18. Doherty MM, Charman WN. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? [J]. Clin Pharmacokinet, 2002,41(4): 235-253.
19. Lee W, Kim RB. Transporters and renal drug elimination [J]. Annu Rev Pharmacol Toxicol, 2004,44:137-166.
20. van Asperen J, van Tellingen O, Beijnen JH. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice [J]. Drug Metab Dispos, 2000,28(3):264-267.
21. Huang SM, Lesko LJ. Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? [J]. J Clin Pharmacol, 2004,44(6):559-569.
22. Su CY. Clinical Pharmacokinetics [M]. Beijing: Science Press, 2003.17-27.